Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies
International Journal of Epidemiology · 2025
DOI: 10.1093/ije/dyaf082 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Epidemiology, 2025. Verfasst von Signe Benzon Larsen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Kirsten and Freddy Johansen Foundation.
Abstract (Originalsprache)
Background
Prostate cancer survival varies across Nordic countries, potentially reflecting variation in stage distribution at diagnosis. To highlight the variation in the diagnostic intensity of prostate cancer, we outlined the differences in stage distributions at diagnosis across these countries. Specifically, we evaluated whether the variation in cancer survival could be attributed to differences in stage at diagnosis.
Methods
In this population-based cohort study, we identified 243 893 men diagnosed with prostate cancer from 2004 to 2016 in Denmark, Iceland, Norway, and Sweden. Country-specific stage distributions at diagnosis were obtained from individual cancer registry records provided by the NORDCAN collaboration. Relative survival and 95% confidence intervals (CIs) were estimated by using the Pohar Perme estimator. Stage-standardized relative survival was estimated by applying pre-weighting based on the stage distribution of the entire Nordic cohort.
Results
The stage distribution of prostate cancer varied between the Nordic countries, with the highest proportion of early-stage (0–I) cases in Sweden and the highest proportion of advanced-stage (IV) cases in Denmark. When adjusting for differences in stage distribution (i.e. stage standardization), the 5-year relative survival improved in Denmark and Norway within the study period (2004–17), increasing from 83.9% (95% CI, 83.2–84.6) and 91.4% (95% CI, 90.8–92.0) to 87.3 (95% CI, 86.5–88.2) and 93.4% (95% CI, 92.8–94.1). Conversely, the 5-year relative survival declined in Sweden from 90.6% (95% CI, 90.3–91.0) to 88.5% (95% CI, 88.0–89.1).
Conclusion
The distinct differences in stage distributions between the Nordic countries substantially contributed to the variation in prostate cancer survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Section of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- Cancer Survivorship, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Cancer Epidemiology and Surveillance, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
ORCID-Profile: Signe Benzon Larsen, Frida E Lundberg, Therese M-L Andersson, Gerda Engholm, Paul C Lambert, Klaus Brasso, Anna L V Johansson, Lina Steinrud Mørch
Förderung
- Kirsten and Freddy Johansen Foundation
Zitieren
APA
Larsen, S. B., Lundberg, F. E., Friis, S., Birgisson, H., Andersson, T. M., Engholm, G., Lambert, P. C., Brasso, K., Pettersson, D., Ólafsdóttir, E., Johannesen, T. B., Kønig, S. M., Johansson, A. L. V., & Mørch, L. S. (2025). Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyaf082
Vancouver
Larsen SB, Lundberg FE, Friis S, Birgisson H, Andersson TM, Engholm G, et al. Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies. International Journal of Epidemiology. 2025. doi:10.1093/ije/dyaf082
BibTeX
@article{Larsen2025,
author = {Larsen, Signe Benzon and Lundberg, Frida E and Friis, Søren and Birgisson, Helgi and Andersson, Therese M-L and Engholm, Gerda and Lambert, Paul C and Brasso, Klaus and Pettersson, David and Ólafsdóttir, Elínborg and Johannesen, Tom Børge and Kønig, Simon M and Johansson, Anna L V and Mørch, Lina Steinrud},
title = {Stage-standardized and stage-specific survival among men with prostate cancer in the Nordic countries 2004–16: the NORDCAN survival studies},
journal = {International Journal of Epidemiology},
year = {2025},
doi = {10.1093/ije/dyaf082}
}
EUVIMED